Publications
Detailed Information
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial
Cited 0 time in
Web of Science
Cited 0 time in Scopus
- Authors
- Issue Date
- 2017-09-22
- Publisher
- BioMed Central
- Citation
- Trials, 18(1):439
- Keywords
- Endovascular treatment ; Sarpogrelate ; Peripheral artery disease ; Stenosis ; Femoro-popliteal
- Description
- Abbreviations
ABI: Ankle–brachial index; CTA: Computed tomography angiography; CVD: Cardiovascular disease; DAPT: Dual antiplatelet therapy; EVT: Endovascular treatment; FP: Femoro-popliteal; PAD: Peripheral artery disease; PCI: Percutaneous coronary intervention; TASC: Transatlantic InterSociety Consensus
- Abstract
- Abstract
Background
Sarpogrelate is expected to reduce restenosis by protecting blood vessels from oxidative stress and vascular endothelial dysfunction as well as by acting as an antiplatelet agent after endovascular treatment (EVT). This trial was designed to compare aspirin plus sustained-release (SR) sarpogrelate with aspirin plus clopidogrel for the prevention of restenosis in patients with femoro-popliteal (FP) peripheral artery disease (PAD) who underwent EVT.
Methods/Design
This is an open label, multicenter, prospective randomized controlled clinical trial. Patients will be eligible for inclusion in this study if they require EVT for stenosis or occlusion of a de novo FP lesion. Patients in each group will receive aspirin 100mg with clopidogrel 75mg or aspirin 100mg with SR sarpogrelate 300mg (Anplone®) orally once a day for six months. The primary outcome of the study is the restenosis rate, defined as > 50% luminal reduction by computed tomography angiography or catheter angiography in the six-month follow-up period. Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months.
Discussion
This study is a multicenter randomized controlled trial designed to show non-inferiority in terms of the re-stenosis rate of SR sarpogrelate compared to clopidogrel for EVT for PAD in FP lesion patients.
- ISSN
- 1745-6215
- Language
- English
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.